Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients a phase III study

Immunological Investigations

Volumn 39, Issue 6, 2010, Pages 570-586

  Wright, Stephen E ^a,b,c   Rewers Felkins, Kathleen A ^a,b,c   Quinlin, Imelda S ^a,b,c   Phillips, Catherine A ^a,b   Townsend, Mary ^d   Philip, Ramila ^e   Zorsky, Paul ^b,c   Klug, Panpit ^b,c   Dai, Lijun ^a,b   Hussain, Mohammad ^a,b   Thomas, Aabu A ^a,b   Sundaramurthy, Chithraleka ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Harrington Cancer Center   (United States)

^d Coffee Memorial Blood Bank ^*  (United States)

^e Immunotope Inc   (United States)

Author keywords

Adoptive immunotherapy; CTL; Human; MUC1; Stimulation

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; MUCIN 1; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADULT; APHERESIS; ARTICLE; BREAST CANCER; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; IMMUNOPHENOTYPING; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; LYMPHOKINE ACTIVATED KILLER CELL; MEMORY T LYMPHOCYTE; METASTASIS; NATURAL KILLER CELL; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REMISSION; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKAPHERESIS; MUCIN-1; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 77954975774     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820131003713798     Document Type: Article

References (42)

1. Apostolopoulos, V., Osinski, C., McKenzie, I.F. (1998). MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral [see comments]. Nat. Med. 4:315-320.
2. Apostolopoulos, V., Barnes, N., Pietersz, G. A., McKenzie, I.F. (2000). Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18:3174-3184.
3. Barnd, D. L., Lan, M. S., Metzgar, R. S., Finn, O. J. (1989). Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86:7159-7163.
4. Cancer Therapy Evaluation Program; DCTD; NCI; NIH; DHHS (1998): Common Toxicity Criteria, Version 2.0 (CTC). (Available at: http://ctep.info.nih.gov/ reporting/ctc.html Accessed April 30, 1999; Cancer Therapy Evaluation Program).
5. Chang, A. E., Yoshizawa, H., Sakai, K., Cameron, M. J., Sondak, V. K., Shu, S. (1993). Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53:1043-1050.
6. den Haan, J. M., Meadows, L. M., Wang, W., Pool, J., Blokland, E., Bishop, T. L., Reinhardus, C., Shabanowitz, J., Offringa, R., Hunt, D. F., Engelhard, V. H., Goulmy, E. (1998). The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054-1057.
7. Drobyski, W. R., Keever, C. A., Roth, M. S., Koethe, S., Hanson, G., McFadden, P., Gottschall, J. L., Ash, R. C., van Tuinen, P., Horowitz, M. M., et al. (1993). Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318.
8. Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J. P., Citrin, D. E., Leitman, S. F., Wunderlich, J., Restifo, N. P., Thomasian, A., Downey, S. G., Smith, F. O., Klapper, J., Morton, K., Laurencot, C., White, D. E., Rosenberg, S.A. (2008): Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32):5233-5239.
9. Falkenburg, J. H., Wafelman, A. R., Joosten, P., Smit, W. M., van Bergen, C. A., Bongaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J. E., Kluin-Nelemans, H. C., Fibbe, W. E., Willemze, R. (1999). Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94:1201-1208.
10. Fass, L., Fefer, A. (1972). Studies of adoptive chemoimmunotherapy of a Friend virusinduced lymphoma. Cancer Res. 32:997-1001.
11. Fefer, A., Sullivan, K. M., Weiden, P., Buckner, C. D., Schoch, G., Storb, R., Thomas, E. D. (1987). Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 244:401-408.
12. Gendler, S. J., Spicer, A. P., Lalani, E. N., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Boshell, M., Taylor-Papadimitriou, J. (1991). Structure and biology of a carcinomaassociated mucin, MUC1. Am. Rev. Respir. Dis. 144:S42-S47.
13. Habib-Agahi, M., Phan, T. T., Searle, P. F. (2007). Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol. 19(12):1383-1394 Epub 2007 Oct 31.
14. Higano, C. S., Brixey, M., Bryant, E. M., Durnam, D. M., Doney, K., Sullivan, K. M., Singer, J. W. (1990). Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graftversus-leukemia effect. Transplantation 50:175-177.
15. Hiltbold, E. M., Ciborowski, P., Finn, O. J. (1998). Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 58:5066-5070.
16. Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., Yee, C. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358:2698-2703.
17. Ioannides, C. G., Fisk, B., Jerome, K. R., Irimura, T., Wharton, J. T., Finn, O. J. (1993). Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151:3693-3703.
18. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F., Bast, R. C., Jr., Finn, O. J. (1991). Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908-2916.
19. Jin, Y., Giri, C., Klutch, M.J., Shepp, D., Wright, S.E. (1993). Improved immunogenicity of recombinant vaccinia virus-anchored gp120 lacking gp41. Vaccine 11:1280-1282.
20. Karanikas, V., Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., McKenzie, I. F. (1997). Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100:2783-2792.
21. Kolb, H. J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., Wilmanns, W. (1990). Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465.
22. Kornbluth, J., Flomenberg, N., Dupont, B. (1982). Cell surface phenotype of a cloned line of natural killer cells. J. Immunol. 129:2831-2837.
23. Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., Andreesen, R. (2006). Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24:5060-5069.
24. Meidenbauer, N., Marienhagen, J., Laumer, M., Vogl, S., Heymann, J., Andreesen, R., Mackensen, A. (2003). Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2161-2169.
25. Mitchell, M. S., Darrah, D., Yeung, D., Halpern, S., Wallace, A., Voland, J., Jones, V., Kan-Mitchell, J. (2002). Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20: 1075-1086.
26. Odom, L. F., August, C. S., Githens, J. H., Humbert, J. R., Morse, H., Peakman, D., Sharma, B., Rusnak, S. L., Johnson, F. B. (1978). Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus- leukaemia reaction" in man?Lancet 2:537-540.
27. Prenndergast, G. C., Jaffee, E. M. (2007). Cancer Immunotherapy: Immune Suppression and Tumor Growth, 13th ed. Academic Press/Elsevier:Amsterdam, 2007.
28. Pulvertaft, R. J. V. (1964). Cytology of Burkitt's tumour (Afrikan Lymphoma). Lancet 1:238-240.
29. Quinlin, I. S., Burnside, J. S., Dombrowski, K. E., Phillips, C. A., Dolby, N., Wright, S. E. (2007). Context of MUC1 epitope: immunogenicity. Oncol. Rep. 17:453-456
30. Roskrow, M.A., Suzuki, N., Gan, Y.j, Sixbey, J.W., Ng, C.Y., Kimbrough, S., Hudson, M., Brenner, M.K., Heslop, H.E., Rooney, C.M. (1998). Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91:2925-2934.
31. Ross, S., Osband, M. (1989). Treatment of metastatic renal cell carcinoma (RCC) with autloymphocyte therapy. Correlation between survival and the number of infused lymphocytes. FASEB J. 3(3, Part 1):A825 (Abstr 3482).
32. Straathof, K. C. M., Bollard, C. M., Popat, U., Huls, M. H., Lopez, T., Morriss, M. C., Gresik, M., V, Gee, A. P., Russell, H., V, Brenner, M. K., Rooney, C. M., Heslop, H. E. (2005): Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005 Mar 1,105(5):1898-1904. Epub 2004 Nov 12.
33. Sullivan, K. M., Weiden, P. L., Storb, R., Witherspoon, R. P., Fefer, A., Fisher, L., Buckner, C. D., Anasetti, C., Appelbaum, F. R., Badger, C., et al. (1989). Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720-1728. (Pubitemid 19133213)
34. Toh, U., Yamana, H., Sueyoshi, S., Tanaka, T., Niiya, F., Katagiri, K., Fujita, H., Shirozou, K., Itoh, K. (2000). Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin. Cancer. Res. 6:4663-4673.
35. Topalian, S. L., Solomon, D., Avis, F. P., Chang, A. E., Freerksen, D. L., Linehan, W. M., Lotze, M. T., Robertson, C. N., Seipp, C.A., Simon, P., et al. (1988). Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839-853.
36. Tricot, G., Vesole, D. H., Jagannath, S., Hilton, J., Munshi, N., Barlogie, B. (1996). Graft-versus-myeloma effect: proof of principle. Blood 87:1196-1198.
37. Ueno, N. T., Rondon, G., Mirza, N. Q., Geisler, D. K., Anderlini, P., Giralt, S. A., Andersson, B. S., Claxton, D. F., Gajewski, J. L., Khouri, I. F., Korbling, M., Mehra, R. C., Przepiorka, D., Rahman, Z., Samuels, B. I., van Besien, K., Hortobagyi, G. N., Champlin, R. E. (1998). Allogeneic peripheral-blood progenitorcell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16:986-993.
38. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., Riddell, S. R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
39. Wright, S. E., Kilinski, L., Talib, S., Lowe, K. E., Burnside, J. S., Wu, J. Y., Dolby, N., Dombrowski, K. E., Lebkowski, J. S., Philip, R. (2000). Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J. Immunother. 23:2-10.
40. Wright, S. E., Khaznadar, R., Wang, Z., Quinlin, I. S., Rewers-Felkins, K. A., Phillips, C. A., Patel, S. (2008). Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand. J. Immunol. Jan 67(1):24-29.
41. Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
42. Zhou, J., Shen, X, Huang, J., Hodes, R. J., Rosenberg, S. A., Robbins, P. F. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175:7046-7052.